Compare IDEXX Laboratories, Inc. (IDXX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Repligen Corporation Common Stock — how do they compare? IDEXX Laboratories, Inc. trades at $532.96 (market cap $41.68B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.7× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and Repligen Corporation Common Stock for 0 Days on average.
| IDXX | RGEN | |
|---|---|---|
Market Cap | $41.68B | $11.31B |
Volume | 824,427 | 1,216,919 |
Sector | Health | Health |
52-Week High | $766.68 | $194.57 |
52-Week Low | $504.70 | $102.87 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $42.58B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $520.31, down 0.69% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.27 versus $3.94, maintaining a 3-quarter beat streak. Revenue growth accelerated to $4.3B in 2025 with robust 25.03% net margins and exceptional 74.21% ROE. Recent acquisitions like CoVetAI expand veterinary workflow capabilities while management reaffirmed long-term growth targets at the Morgan Stanley Healthcare Conference.
Wall Street maintains bullish sentiment with 56.5% buy ratings and $665 consensus target implying 28% upside. Strong profitability and diagnostic innovation pipeline support growth, though elevated P/E of 37.2 and recent insider selling pose valuation concerns. Key risks include FX headwinds, weaker U.S. vet visits, and competitive pressures in veterinary diagnostics.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
